Articles tagged with Antibody Therapy
A Phase IIa international study found that a combination of zanidatamab, palbociclib, and fulvestrant improved progression-free survival by 12 months with durable responses. The treatment regimen is being developed for heavily pretreated patients with HER2+/HR+ metastatic breast cancer.
Researchers have provided new details on structures resulting from 3D domain swapping in antibody light chains, shedding light on mechanisms of protein aggregation. The study suggests that the formation of tetramers may prevent protein aggregation by decreasing flexibility.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers found that a breakthrough infection builds upon existing memory B cell pool and introduces random mutations that prepare antibodies for new variants. Broad neutralizing antibodies can neutralize all tested Omicron variants.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
Human noroviruses cause over 684 million illnesses and 212,000 deaths annually. Researchers discovered that llama nanobodies can effectively neutralize different norovirus strains by recognizing a hidden pocket in the virus particles. This finding suggests a novel therapeutic approach against human norovirus.
Researchers found that vaccination increases immune cell production and antibody levels effective against all tested variants of SARS-CoV-2, including Omicron. Convalescent plasma therapy research provides insight into how the body fights COVID-19 variants.
Researchers analyzed fish IgM to understand its structure and how it differs from human antibodies. They discovered a unique folding mechanism that allows the antibody to assemble without a joining chain, enabling it to bind antigens and interact with its environment.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
Treatment with obinutuzumab has been shown to preserve kidney function and prevent flares in patients with lupus nephritis. The addition of obinutuzumab to standard treatment reduced the risk of composite outcomes, such as death or treatment failure, by 60%.
A new study finds that people with antibodies to common foods like dairy and peanuts are at a higher risk of cardiovascular-related death. The research suggests that these subtle immune responses may lead to inflammation and contribute to heart disease over time.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
Researchers at the German Center for Infection Research have developed effective antibodies against Pseudomonas aeruginosa, a major challenge in healthcare systems worldwide. These monoclonal antibodies target the pathogen's type III secretion system and show promise as a highly potent treatment option for acute and chronic infections.
A new antibody created by Cold Spring Harbor Laboratory researchers may offer an effective treatment for some breast cancers. The antibody targets the PTPRD enzyme, which is overabundant in certain breast cancers and helps them spread.
Researchers at Duke University developed an innovative antibody approach to target and kill tumor-promoting molecules found in cancer cells. The study revealed notable reductions in tumor growth and minimal side effects, making it a promising new treatment option for various types of cancer.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
A team of researchers from Mass General Brigham has developed a monoclonal antibody that reduces abnormal tau proteins associated with Alzheimer's disease in a preclinical model. The therapy, inspired by a genetic variant that provides resistance against the disease, offers an alternative approach to existing treatments.
A retrospective analysis of 37 heavily pretreated multiple myeloma patients found that intravenous immunoglobulin (IVIg) reduced the risk of severe infections by 90%. Patients with hypogammaglobulinemia experienced a higher rate of severe infections, and IVIg supplementation significantly mitigated this risk.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
A breakthrough discovery identifies cis P-tau as a central circulating driver of preeclampsia. The antibody targets this toxic protein, correcting features associated with the condition and eliminating symptoms in mouse models.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
Brigham researchers discovered a nasal immunotherapy approach that reduces inflammation and improves cognitive function in Alzheimer's mouse models. The treatment also expands regulatory T cells and changes gene expression patterns in the brain.
A study by Mass General Brigham researchers found that patients with rheumatic diseases who developed long COVID were more likely to have expanded, pro-inflammatory antibodies specific to a coronavirus that causes the common cold. The team identified OC43 as a potential biomarker for long COVID.
A team of UC Irvine scientists discovered a llama-derived antibody called a nanobody that can halt Rhodopsin's misfolding and activation, potentially treating Retinitis Pigmentosa. This breakthrough offers new hope for targeting gene therapies for the condition.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
A new article published in RadioGraphics warns of a potential side effect of novel Alzheimer's treatments: amyloid-related imaging abnormalities (ARIA). ARIA can cause swelling or bleeding in the brain and may be asymptomatic. Radiologists must monitor for ARIA to plan image monitoring per established guidelines.
Research identifies immunosuppressed individuals with lower antibody prevalence after three or more COVID-19 vaccine doses, highlighting increased vulnerability to severe infection. The MELODY study found that around one in five people with compromised immune systems had no COVID-19 antibodies.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers have identified key genes involved in producing large amounts of immunoglobulin G, a crucial antibody in the human body. The discovery could lead to advancements in manufacturing antibody-based therapies for diseases such as cancer and arthritis.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
A preclinical study demonstrates the effectiveness of VIR-3434 in preventing viral dissemination and reducing viral particles in a mouse model for HBV/HDV coinfection. The monoclonal antibody neutralises all known genotypes of HBV and HDV, providing a potential new option for treating chronic hepatitis B and D.
A human antibody that targets carfentanil, fentanyl, and related opioids has shown promising results in reversing overdose effects in a preclinical study. The antibody, developed by Scripps Research, binds tightly to the potent opioid variants and reverses respiratory depression caused by carfentanil.
Scientists studied 470 sera from vaccinated or MPXV-infected individuals to elucidate mechanisms involved in post-infectious immune response. The study revealed the role of complement and analyzed immune responses in vaccinated or infected individuals, with robust levels of anti-MVA antibodies detected after infection or vaccination.
Researchers discovered GDF-15 blocks LFA-1 dependent T cell recruitment into the tumor microenvironment, impairing immune responses to anti-PD-1 treatment. Visugromab improved T cell infiltration and increased tumor clearance with a synergistic effect
Researchers have identified a new therapeutic target for glioblastoma brain cancer by finding that the 'don't eat me!' signal sent by cancer cells can be blocked using antibodies. This breakthrough suggests that existing immunotherapies may be effective against glioblastomas if the receivers on macrophages are switched off.
A new combination treatment of GVAX vaccine, nivolumab, and urelemab has shown to increase the amount of cancer-killing immune cells in tumors and appear effective when given two weeks prior to surgery. The study found a median disease-free survival of 33.51 months and a median overall survival of 35.5 months.
Researchers discover the key to modulating immune reactions by fine-tuning antibodies. The backbone of Y-shaped immunoglobulins plays a crucial role, with posttranslational modifications controlling the strength of the reaction.
The new Clinical Research Unit will investigate autoantibodies' role in neurological disorders, focusing on diagnosis and treatment. Researchers expect innovative therapies for patients with previously suspected diseases.
In a groundbreaking procedure, Adriana Rodriguez received a dual-organ transplant, with her healthy liver transplanted into another patient to mitigate rejection risk. This innovative approach, known as HALT-D, demonstrates the potential for immunoprotection and has implications for highly sensitized patients requiring multiple organs.
Researchers discovered a novel peptide, T14, that is detectable in human keratinocytes and inversely related to age, with higher levels found in chronically photosensitive individuals. The study suggests that monitoring T14 levels may offer insights into the link between degenerative diseases and epidermal cell profiles.
Researchers identified four therapeutic monoclonal antibody candidates that neutralized a range of SARS-CoV-2 variants. Prolonged exposure to the virus triggered somatic hypermutations, equipping these antibodies with an extensive binding interface.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
CHOP researchers have developed stable, universal MHC-I molecules that can be produced rapidly at scale, allowing for the development of effective and universal immunotherapies. These engineered MHC-I molecules promote peptide exchange across multiple HLA allotypes, covering various forms.
Researchers found that targeting CD69 boosts the differentiation of tumor-specific CD8+ T cells in lymph nodes, promoting enhanced anti-tumor activity. This discovery identifies CD69 as a promising therapeutic target for future cancer immunotherapies.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have developed a new therapy that uses engineered macrophages to eliminate solid tumors. The treatment works by silencing a molecular pathway that prevents white blood cells from attacking cancer cells, allowing them to recognize and destroy tumoroids.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Scientists at Scripps Research have determined the structure of the critical protein complex that lets Lassa virus infect human cells, identifying new antibodies and vaccine targets. The research also found a high level of conservation across different lineages of the virus, paving the way for more effective vaccines and treatments.
A case study published in the Journal of Alzheimer's Disease reveals that lecanemab can lead to therapy-induced Aβ phagocytosis and multifocal intracerebral hemorrhage, highlighting a potential risk of brain damage and death. The study suggests that better biomarkers are needed to assess the extent of cerebral amyloid angiopathy.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
Research from Boston Medical Center found that pulmonary tuberculosis enhances HIV antibody responses and increases the prevalence of antibody-resistant strains. This study has significant implications for HIV vaccines and antibody-based therapies, highlighting the need for novel strategies to generate broad and potent antibodies.
A new immunotherapy treatment developed by UCF researchers uses targeted IL-2 to fight respiratory viral infections with improved outcomes in animal studies. The treatment promotes an antiviral inflammatory response and reduces bronchial inflammation.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.